2Bio Ltd. is pleased to announce that it has entered into a partnership with IBMC – Instituto de Biologia Molecular e Celular – to manage and commercialise its Intellectual property.

IBMC is a multidisciplinary research institution that brings together researchers working within the University of Porto, and affiliated hospitals, to produce a unique environment for research in the life sciences; it is recognised and funded by the Foundation for Science and Technology (FCT) of Portugal; the main Portuguese government body that funds science.

2Bio’s Impact Science Team will be deployed to evaluate technologies for their commercial potential, create commercialisation strategies and develop new business value for IBMC.

The work will also encompass all aspects of IP protection and management, integrating with IBMC’s own Tech Transfer Office.

The Impact Science Team has a strong track record of IP and market analysis in the life sciences sector, and has supported the creation of new business value for a wide range of international clients. The team has worked together for more than 10 years and draws on both science and business expertise in a wide range of disciplines.

Dr. Rhys Roberts, 2Bio’s co-founder said “this important strategic partnership gives 2Bio the opportunity to work seamlessly with the outputs of IBMC’s research excellence; we expect to identify and deliver valuable business outcomes for IBMC, and provide channels to reach global markets. We have been very impressed with what we have seen so far, from both the research and the leadership at the Institute”.

Professor Claudio Sunkel, IBMC Director, said “This partnership with 2Bio is the start of a new approach to explore Technology Transfer within our institute and we are all very excited to begin the process of detailed exploration of the technologies developed at our institute. IBMC’s main research interests are in the areas of Neurodegenerative diseases, Host-Pathogen Interactions and various aspects of Molecular and Cellular Biology related to Cell Division and Cancer.  We are confident that this partnership will be crucial in finding the appropriate routes for the commercialization of our human-related work, as well as our proven model organisms including mouse models”